MoonLake Immunotherapeutics AG – Trademark Portfolio
Entity Type: 99
MoonLake Immunotherapeutics AG holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 5 trademarks are registered and 1 is pending. Notable registered marks include EMBODVY, ENBODVY, MOONLAKE, RAIZINBI, and REYSONFY.
Dorfstrasse 29
CH-6300 Zug
Showing of trademarks Trademarks
Trademark Classifications
MoonLake Immunotherapeutics AG's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does MoonLake Immunotherapeutics AG have?
MoonLake Immunotherapeutics AG has 8 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 pending, 1 abandoned, 1 cancelled.
What trademark classes does MoonLake Immunotherapeutics AG file in?
MoonLake Immunotherapeutics AG files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are MoonLake Immunotherapeutics AG's most well-known trademarks?
MoonLake Immunotherapeutics AG's registered trademark portfolio includes well-known marks such as EMBODVY, ENBODVY, MOONLAKE, RAIZINBI, and REYSONFY. These are among 5 currently registered trademarks in the portfolio.
What is MoonLake Immunotherapeutics AG's trademark registration success rate?
MoonLake Immunotherapeutics AG has a 71% trademark registration rate, with 5 out of 7 resolved applications resulting in successful registration. Currently, 1 application is pending review.